Remerciez-le!

Remerciez @Admin pour avoir partagé cet document gratuitement, de la manière la plus simple, en partageant sur les réseaux sociaux.

Resource guide the pfizer biontech covid 19 vaccine 1

THE PFIZER-BIONTECH COVID- VACCINE RESOURCE GUIDE Your guide to utilizing the P ?zer-BioNTech COVID- Vaccine resources The P ?zer-BioNTech COVID- Vaccine has not been approved or licensed by FDA but has been authorized for emergency use by FDA under an Emergency Use Authorization to prevent Coronavirus Disease COVID- for use in individuals years of age and older The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section b of the FD C Act unless the declaration is terminated or authorization revoked sooner Before administration of P ?zer-BioNTech COVID- Vaccine please see Emergency Use Authorization EUA Fact Sheet for Healthcare Providers Administering Vaccine Vaccination Providers including Full EUA Prescribing Information available at www cvdvaccine-us com Current as of June For the most up-to-date information visit www cvdvaccine-us com ABOUT THIS RESOURCE GUIDE This guide contains resources designed to assist you and your vaccination site in handling and administering the P ?zer- BioNTech COVID- Vaccine Learn about each resource and how it can help ensure the vaccine is handled and administered correctly according to the dosing schedule These resources are also available at www cvdvaccine- us com IMPORTANT SAFETY INFORMATION ? Do not administer P ?zer-BioNTech COVID- Vaccine to individuals with known history of a severe allergic reaction eg anaphylaxis to any component of the P ?zer-BioNTech COVID- Vaccine ? A ppropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of P ?zer- BioNTech COVID- Vaccine Monitor P ?zer-BioNTech COVID- Vaccine recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control and Prevention guidelines https www cdc gov vaccines covid- clinical-considerations managing- anaphylaxis html ? R eports of adverse events following use of the P ?zer- BioNTech COVID- Vaccine under EUA suggest increased risks of myocarditis and pericarditis particularly following the second dose The decision to administer the P ?zer-BioNTech COVID- Vaccine to an individual with a history of myocarditis or pericarditis should take into account the individual ? s clinical circumstances ? S yncope fainting may occur in association with administration of injectable vaccines in particular in adolescents Procedures should be in place to avoid injury from fainting ? I mmunocompromised persons including individuals receiving immunosuppressant therapy may have a diminished immune response to the P ?zer-BioNTech COVID- Vaccine ? The P ?zer-BioNTech COVID- Vaccine may not protect all vaccine recipients ? I n clinical studies adverse reactions in participants years of age and older included pain at the injection site fatigue headache muscle pain chills joint pain fever injection site swelling injection site redness nausea malaise and lymphadenopathy ? I n a clinical study adverse reactions in adolescents through years of age included pain at the injection site fatigue headache chills muscle pain fever joint pain injection site swelling injection site redness lymphadenopathy and nausea ? F ollowing administration of the